Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying

The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Entera Bio

• The Trade: Entera Bio Ltd. (NASDAQ:ENTX) Director Haya Taitel acquired a total of 7,615 shares an average price of $0.77. To acquire these shares, it cost around $5,86.
• What’s Happening: Entera Bio announced that it received an extension of 180 calendar days from the Nasdaq stock market to regain compliance.
• What Entera Bio Does: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins.

OPKO Health

• The Trade: OPKO Health, Inc. (NASDAQ:OPK) 10% owner Frost Gamma Investments Trust acquired a total of 511,531 shares at at an average price of $0.94. To acquire these shares, it cost around $480,379.
• What’s Happening: OPKO Health recently priced private offering of $200 million convertible senior notes due 2029.
• What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.

Check This Out: Citigroup, Bank of America And 3 Stocks To Watch Heading Into Friday

Fresh Tracks Therapeutics

• The Trade: Fresh Tracks Therapeutics, Inc. (OTC:FRTX) 10% owner Exploration Capital LLC acquired a total of 51,502 shares at an average price of $0.98. The insider spent around $50,472 to buy those shares.
• What’s Happening: Fresh Tracks Therapeutics plans to hold new special meeting of stockholders on Feb. 15, 2024 to seek stockholder approval of liquidation.
• What Fresh Tracks Therapeutics Does: Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Vista Gold

• The Trade: Vista Gold Corp. (NYSE:VGZ) Director Tracy Austin Stevenson acquired a total of 20,000 shares at an average price of $0.37. The insider spent around $7,324 to buy those shares.
• What’s Happening: Vista Gold recently announced it will receive $20 million from Wheaton Precious Metals as part of a royalty agreement in relation to the company's Mt Todd gold project.
• What Vista Gold Does: Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects.

Don’t forget to check out our premarket coverage here